Kazimierz Kuliczkowski

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway

Jizhong Liu, Abdelbasset Hamrouni, Dariusz Wołowiec et al. · Blood · 2007 · 576 citations · Full text

Medicine, Hematology, Immunology +8

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis

Animesh Pardanani, Claire Harrison, Jörge E. Cortes et al. · JAMA Oncology · 2015 · 472 citations

Medicine, Hematology, Pharmacology +14

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles et al. · Blood · 2007 · 291 citations · Full text

Medicine, Oncology, Pharmacology +4

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

Jerzy Hołowiecki, Sebastian Grosicki, Sebastian Giebel et al. · Journal of Clinical Oncology · 2012 · 264 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Gustaaf W. van Imhoff, Andrew McMillan, Matthew J. Matasar et al. · Journal of Clinical Oncology · 2017 · 237 citations · Full text

Medicine, Immunology, Oncology +14